Aberrant prostaglandin synthase 2 expression defines an antigen- presenting cell defect for insulin-dependent diabetes mellitus

Journal of Clinical Investigation

Volumn 104, Issue 4, 1999, Pages 515-523

  Litherland, S A ^a   Xie, X T ^a   Hutson, A D ^b   Wasserfall, C ^a   Whittaker, D S ^a   She, J X ^a   Hofig, A ^a   Dennis, M A ^a   Fuller, K ^a   Cook, R ^a   Schatz, D ^a   Moldawer, L L ^a   Clare Salzler, M J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SCHOOL CHILD; T LYMPHOCYTE ACTIVATION;

EID: 0032694583     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI4852     Document Type: Article

References (58)

1. Ashton-Richardt, P.G., et al. 1994. Evidence of a differential avidity model of T cell selection in the thymus. Cell. 76:651-663.
2. Sebzda, E., et al. 1994. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science. 263:1615-1618.
3. Rocha, B., and von Boehemer, H. 1991. Peripheral selection of the T cell repertoire. Science. 251:1225-1231.
4. Zhang, L., Martin, D.R., Fung-Leung, W.-P., Te, H.-S., and Miller, R.G. 1992. Peripheral deletion of mature CD8+ antigen specific T cells after in vivo exposure to male antigen. J. Immunol. 148:1538-1592.
5. Ucker, D.S., Meyers, J., and Obermiller, P.S. 1993. Activation-driven T cell death. II. Quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death. J. Immunol. 149:1583-1592.
6. Critchfield, J.M., et al. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1139-1143.
7. Pelfry, C.M., Tranquill, L.R., Boehme, S.A., McFarland, H.F., and Lenardo, M.J. 1995. Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-spectfic T lymphocytes derived from multiple sclerosis patients and normal individuals. J. Immunol. 154:6191-6202.
8. Ishikura, H., et al. 1995. Functional analysis of cloned macrophage hybridomas. VII. Modulation of suppressor T cell inducing activity. J. Immunol. 154:6191-6020.
9. Yokono, K., Kasase, Y., Nagata, M., Hatamori, N., and Baba, S. 1989. Suppression of concanavalin A-induced responses in splenic lymphocytes by activated macrophages in the non-obese diabetic mouse. Diabetologia. 32:67-73.
10. Ransanen, L., et al. 1989. Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo activated T lymphocytes. Clin. Immunol. Immunopathol. 32:67-73.
11. Smerdon, R.A., et al. 1993. Increases in simultaneous co-expression of naive and memory lymphocyte markers at diagnosis of IDDM. Diabetes. 42:127-132.
12. De Maria, R., et al. 1994. Defective T cell receptor/CD3 complex signaling in human type 1 diabetics. Eur. J. Immunol. 24:999-1002.
13. Serreze, D.V., Gaskins, H.R., and Leiter, E.H. 1993. Defective activation of T suppressor cell function in nonobese diabetic mice: potential relationship to cytokine deficiencies. J. Immunol 150:2534-2543.
14. Millich, D.R., et al. 1989. Distinction between antigenicity and tolerogenicity among HbcAg T cell determinants: influence of peptide MHC interaction. J. Immunol. 143:3148-3156.
15. Mamula, M.J. 1993. The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J. Exp. Med. 17:567-571.
16. Wicker, L.S., et al. 1992. Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes. J. Exp. Med. 156:450-458.
17. Prochazka, M., Serreae, D.V., Worthern, S.M., and Leiter, E.H. 1989. Generic control of diabetogenesis in NOD.Lt mice: development and analysis of congenic stocks. Diabetes. 38:1446-1455.
18. Wicker, L.S., Todd, J.A., and Peterson, L.B. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13:179-200.
19. Merriman, T.R., and Todd, J.A. 1996. Genetics of insulin-dependent diabetes: non-major histocompatibility genes. Horm. Metab. Res. 28:289-293.
20. Kawase, Y., et al. 1989. Cellular immune dysfunction in the NOD mouse: suppression of concanavalin A-induced responses in spleen cells by activated macrophages. Nippon Naibunpi Gakkai Zasshi. 65:674-685.
21. Lety, M.A., Coulaud, J., Bens, M., Dardenne, M., and Homo-Delarche, F. 1992. Enhanced metabolism of arachidonic acid by macrophages from nonobese diabetic (NOD) mice. Clin. Immunol. Immunopathol. 64:188-96.
22. Benhamou, P.Y., et al. 1995. Essential fatty acid deficiency prevents autoimmune diabetes in nonobese diabetic mice through a positive impact on antigen-presenting cells and Th2 lymphocytes. Pancreas. 11:26-37.
23. DeWitt, D., and Smith, W.L. 1995. Yes, but do they still get headaches? Cell. 83:345-348.
24. Sweet, M.J., and Hume, D.A. 1996. Endotoxin signal transduction in macrophages. J. Leukoc. Biol. 60:8-26.
25. Cremion, C., et al. 1995. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical endothelial cells using specific immunometric enzyme immunoassays. Biochim. Biophys. Acta. 1254:341-348.
26. Morita, I., et al. 1995. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270:10902-10908.
27. Hemple, S.L., Moick, M., and Hunninghake, G.W. 1993. Lipopolysaccharide induces prostaglandin synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Invest. 93:391-396.
28. Phillips, T.A., Kujubo, D.A., Herschman, H.R., Russel, S.W., and Pace, J.L. 1993. The mouse macrophage activation associated marker protein p71/73 in an inducible prostaglandin endoperoxide synthase (cyclooxygenase). J. Leukoc. Biol. 53:411-419.
29. Schindler, C., and Darnell, J.E., Jr. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64:621-651.
30. Wehinger, J., et al. 1996. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 394:365-370.
31. Anastassiou, E.D., Paliogianni, F., Balow, J.P., Yamada, H., and Boumpas, D.T. 1992. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148:2845-2952.
32. Foegh, M.L. 1988. Immune regulation by eicosanoids. Transplant. Proc. 20:1151-1161.
33. + T lymphoblasts. J. Immunol. 154:1041-1047.
34. Hilkens, C.M., et al. 1996. Accessory cell-derived IL-12 and prostaglandin E2 determine the IFN-gamma level of activated human CD4+ T cells. J. Immunol. 156:1722-1727.
35. Hilkens, C.M., et al. 1995. Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur. J. Immunol. 25:59-63.
36. Paliogianni, F., Kincaid, R.L., and Boumpas, D.T. 1993. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J. Exp. Med. 178:1813-1817.
37. Snijdewint, F.G., Kalinski, P., Wierenga, E.A., Bos, J.D., and Kapsenberg, M.L. 1993. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150:5321-5329.
38. Clare-Salzler, M. 1998. The immunopathogenic roles of antigen presenting cells in the NOD mouse. In NOD mice and related strains: research applications in diabetes, AIDS, cancer, and other diseases. E.H. Leiter and M.A. Atkinson, editors. Landes Bioscience Publishers. Austin, TX. 101-120.
39. vanderPous-Kraan, T.C., Boeije, L.C., Smeenk, R.J., Wijdenes, J., and Aarden, L.A. 1995. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:775-779.
40. Rabinovitch, A. 1994. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes. 43:613-621.
41. Liblau, R.S., Singer, S.M., and McDevitt, H.O. 1995. Th1 andTh2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today. 16:34-38.
42. Charlton, B., and Lafferry, K.J. 1995. The Th1/Th2 balance in autoimmuniry. Curr. Opin. Immunol 7:793-798.
43. Futaki, N., et al. 1994. NS398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:55-59.
44. National Diabetes Data Group. 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1039-1057.
45. Schneider, H. 1986. Truncated and censored samplesfrom normal populations. Marcel Dekker Inc. New York, NY. 129-130.
46. Metz, C.E. 1978. Basic principles of ROC analysis. Semin. Nucl. Med. 8:283-298.
47. Guan, Z., Buckman, S.Y., Baier, L.D., and Morrison, A.R. 1998. IGF-1 and insulin amplify IL-1b-induced nitric oxide and prostaglandin biosynthesis, Am. J. Physiol 274:F673-F679.
48. Dutta-Roy, A.K. 1994. Insulin mediated processes in platelets, erythrocytes and monocytes/macrophages: effects of essential fatty acid metabolism. Prostaglandins Leukot. Essent. Fatty Acids. 51:385-399.
49. Shohami, E., Globus, M., and Weidenfeld, J. 1985. Regional distribution of prostanoids in rat brain: effect of insulin and 2-deoxyglucose. Exp. Brain Res. 61:87-90.
50. Fujii, K., Soma, M., Huang, Y.-S., Manku, M.S., and Horrobin, D.F. 1986. Increased release of prosraglandins from the mesenteric vascular bed of diabetic animals: the effects of glucose and insulin. Prostaglandins Leukot. Med 24:151-161.
51. Avogaro, A., et al. 1996. The hemodynamic abnormalities in short-term insulin deficiency: the role of prostaglandin inhibition. Diabetes. 45:602-609.
52. Mertz, P.M., DeWitt, D.L., Stetler-Stevenson, W.G., and Wehl, LM. 1994. Interleukin 10 suppresses monocyte prostaglandin H synthase-2. J. Biol. Chem. 269:21322-21329.
53. Kneitz, B., Herrman, T., Yonehara, S., and Schimpl, A. 1995. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2 deficient mice. Eur. J. Immunol. 25:2572-2577.
54. Van Parijs, L., Peterson, D.A., and Abbas, A.K. 1998. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity. 8:265-274.
55. Van Parijs, L., and Abbas, A.K. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280:243-248.
56. Refaeli, Y., Van Parijs, L., London, C.A., Tschopp, J., and Abbas, A.K. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Eur.J. Immunol. 8:615-623.
57. Petet, M.E., et al. 1997. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signal complex. Eur. J. Immunol. 27:1207-1212.
58. Theze, J., Alzari, P.M., and Bertoglio, J. 1996. Intetleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today. 17:481-486.